Suppr超能文献

体内使用 siRNAs 的进展 - II。

Progress toward in vivo use of siRNAs-II.

机构信息

Integrated DNA Technologies, Inc., Coralville, Iowa 52241, USA.

出版信息

Mol Ther. 2012 Mar;20(3):483-512. doi: 10.1038/mt.2011.263. Epub 2011 Dec 20.

Abstract

RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.

摘要

RNA 干扰 (RNAi) 自 10 年前首次在哺乳动物细胞中得到证实以来,已被广泛用于体内研究。设计规则得到了改进,现在通常可以获得抑制所需任何基因表达的试剂。与此同时,对不良副作用分子基础的认识不断提高,导致了化学修饰策略的发展,减轻了这些担忧。传递仍然是广泛采用体内 RNAi 方法的最大障碍。然而,令人兴奋的进展已经取得,新的传递系统的发展可能有助于克服这些障碍。这篇综述讨论了影响体内应用的 RNAi 生物化学和生物学方面的进展,并概述了一些展示这些原理有趣应用的精选出版物。重点是 2006 年首次出现本综述以来发表的关于合成小干扰 RNA(siRNA)的工作。

相似文献

1
Progress toward in vivo use of siRNAs-II.体内使用 siRNAs 的进展 - II。
Mol Ther. 2012 Mar;20(3):483-512. doi: 10.1038/mt.2011.263. Epub 2011 Dec 20.
2
Progress towards in vivo use of siRNAs.小干扰RNA(siRNA)体内应用的研究进展。
Mol Ther. 2006 Apr;13(4):644-70. doi: 10.1016/j.ymthe.2006.01.001. Epub 2006 Feb 14.
5
Nonviral delivery of synthetic siRNAs in vivo.体内合成小干扰RNA的非病毒递送
J Clin Invest. 2007 Dec;117(12):3623-32. doi: 10.1172/JCI33494.
6
Therapeutic face of RNAi: in vivo challenges.RNA干扰的治疗前景:体内挑战
Expert Opin Biol Ther. 2015 Feb;15(2):269-85. doi: 10.1517/14712598.2015.983070. Epub 2014 Nov 15.

引用本文的文献

1
Chemical Modifications in Nucleic Acid Therapeutics.核酸疗法中的化学修饰
Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.
4
Strategies for HIV-1 suppression through key genes and cell therapy.通过关键基因和细胞疗法抑制HIV-1的策略。
Front Med (Lausanne). 2023 Nov 29;10:1259995. doi: 10.3389/fmed.2023.1259995. eCollection 2023.
5
Engineering polyphenol-based carriers for nucleic acid delivery.基于多酚的工程化载体用于核酸递送。
Theranostics. 2023 May 21;13(10):3204-3223. doi: 10.7150/thno.81604. eCollection 2023.
8
Intercellular delivery of therapeutic oligonucleotides.治疗性寡核苷酸的细胞间递送。
J Drug Deliv Sci Technol. 2022 Jun;72. doi: 10.1016/j.jddst.2022.103404. Epub 2022 May 10.

本文引用的文献

9
Current progress of siRNA/shRNA therapeutics in clinical trials.siRNA/shRNA 治疗药物在临床试验中的当前进展。
Biotechnol J. 2011 Sep;6(9):1130-46. doi: 10.1002/biot.201100054. Epub 2011 Jul 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验